Company

Vicinitas Therapeutics

Vicinitas Therapeutics develops small-molecule drugs that stabilize targeted proteins.

About

Founded in 2022 by Dan Nomura, Vicinitas Therapeutics is based in San Francisco, US. Its DUBTAC platform uses small molecules to stabilize proteins implicated in diseases including cancer and monogenic disorders. In July 2022, the company raised USD 65 million in Series A funding co-led by Andreessen Horowitz, Deerfield Management, Berkeley Catalyst Fund, and DROIA Ventures.

1Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in